STOCK TITAN

IDEXX (IDXX) EVP Michael Erickson exercises options and sells 5,371 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President Michael G. Erickson reported multiple stock option exercises and related share sales. On February 17, 2026 and February 19, 2026, he exercised incentive and non-qualified stock options and received IDEXX common shares.

On February 17, 2026, he then sold 5,371 shares of common stock in open-market transactions at weighted average prices ranging from about $623.28 to $629.8625 per share. After these transactions, he directly held 12,693.351 shares of IDEXX common stock, including 184 vested but deferred restricted stock units.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Erickson Michael G

(Last) (First) (Middle)
ONE IDEXX DRIVE

(Street)
WESTBROOK ME 04092

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/17/2026 M 1,191 A $141.6 13,884.351 D
Common Stock 02/17/2026 M 4,180 A $178.26 18,064.351 D
Common Stock 02/17/2026 S 456 D $623.7582(1) 17,608.351 D
Common Stock 02/17/2026 S 204 D $625.2423(2) 17,404.351 D
Common Stock 02/17/2026 S 1,288 D $626.2564(3) 16,116.351 D
Common Stock 02/17/2026 S 2,694 D $628.2208(4) 13,422.351 D
Common Stock 02/17/2026 S 689 D $629.0906(5) 12,733.351 D
Common Stock 02/17/2026 S 40 D $629.8625 12,693.351 D
Common Stock 02/19/2026 M 719 A $141.6 13,412.351 D
Common Stock 02/19/2026 M 817 A $178.26 14,229.351 D
Common Stock 02/19/2026 M 483 A $206.94 14,712.351 D
Common Stock 02/19/2026 M 183 A $544.08 14,895.351 D
Common Stock 02/19/2026 M 197 A $505.53 15,092.351(6) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy) $141.6 02/17/2026 M 1,191 (7) 02/13/2027 Common Stock 1,191 $0 0 D
Non-Qualified Stock Option (right-to-buy) $178.26 02/17/2026 M 4,180 (8) 02/13/2028 Common Stock 4,180 $0 0 D
Incentive Stock Option (right-to-buy) $141.6 02/19/2026 M 719 (9) 02/13/2027 Common Stock 719 $0 0 D
Incentive Stock Option (right-to-buy) $178.26 02/19/2026 M 817 (10) 02/13/2028 Common Stock 817 $0 0 D
Incentive Stock Option (right-to-buy) $206.94 02/19/2026 M 483 (11) 02/13/2029 Common Stock 483 $0 0 D
Incentive Stock Option (right-to-buy) $544.08 02/19/2026 M 183 (12) 02/13/2031 Common Stock 183 $0 0 D
Incentive Stock Option (right-to-buy) $505.53 02/19/2026 M 197 (13) 02/13/2032 Common Stock 197 $0 0 D
Explanation of Responses:
1. Represents the weighted average price of the shares sold ranging from a low of $623.28 to a high of $624.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
2. Represents the weighted average price of the shares sold ranging from a low of $624.89 to a high of $625.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
3. Represents the weighted average price of the shares sold ranging from a low of $626.045 to a high of $628.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
4. Represents the weighted average price of the shares sold ranging from a low of $627.74 to a high of $628.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
5. Represents the weighted average price of the shares sold ranging from a low of $628.755 to a high of $629.615 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
6. Includes 184 vested but deferred restricted stock units.
7. Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018.
8. Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2019.
9. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2022.
10. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2023.
11. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024.
12. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2025.
13. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2026.
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for Michael G. Erickson 02/19/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IDEXX (IDXX) executive Michael Erickson report?

Michael G. Erickson reported exercising multiple stock options and selling IDEXX common shares. He completed several option exercises that delivered common stock, then sold 5,371 shares in open-market trades at weighted average prices between $623.28 and $629.8625 per share.

How many IDEXX (IDXX) shares did Michael Erickson sell and at what prices?

Erickson sold 5,371 IDEXX common shares in a series of open-market transactions. The weighted average sales prices ranged from $623.28 to $629.8625 per share, with detailed breakdowns available by individual price range upon request from the issuer or Commission staff.

How many IDEXX (IDXX) shares does Michael Erickson own after these Form 4 transactions?

Following the reported transactions, Michael G. Erickson directly owns 12,693.351 IDEXX common shares. This figure includes 184 vested but deferred restricted stock units, which are credited to his account but deferred rather than currently delivered as freely tradable shares.

What types of equity awards did Michael Erickson exercise in IDEXX (IDXX)?

Erickson exercised both incentive stock options and non-qualified stock options for IDEXX common stock. These options were granted under prior awards that vested in annual or single installments on various February 14 vesting dates from 2018 through 2026, according to the option grant footnotes.

Were Michael Erickson’s IDEXX (IDXX) stock sales reported as open-market transactions?

Yes, the sales were reported with transaction code “S,” indicating open-market or private sales of common stock. Footnotes show each sale’s weighted average price and confirm the company can provide full details about the number of shares sold at each separate price level.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

50.36B
79.30M
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK